Jun Nakata

List of Publications by Year
in descending order

40 papers	608 citations	840776 11 h-index	642732 23 g-index
41 all docs	41 docs citations	41 times ranked	1036 citing authors

#	Article	IF	Citations
1	The activated conformation of integrin Î²7 is a novel multiple myelomaâ€“specific target for CAR T cell therapy. Nature Medicine, 2017, 23, 1436-1443.	30.7	105
2	Wilms Tumor Gene (WT1) Peptideâ€“based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer. Journal of Immunotherapy, 2014, 37, 105-114.	2.4	77
3	Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide. International Journal of Cancer, 2016, 139, 1391-1401.	5.1	43
4	A phase I clinical study of a cocktail vaccine of Wilmsâ€™ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Cancer Immunology, Immunotherapy, 2019, 68, 331-340.	4.2	37
5	Incidence and treatment strategy for disseminated adenovirus disease after haploidentical stem cell transplantation. Annals of Hematology, 2012, 91, 1305-1312.	1.8	34
6	Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy. Oncology Research and Treatment, 2017, 40, 682-690.	1.2	33
7	A Zbtb7a protoâ€oncogene as a novel target for miRâ€125a. Molecular Carcinogenesis, 2016, 55, 2001-2009.	2.7	31
8	WT1 peptideâ€based immunotherapy for advanced thymic epithelial malignancies. International Journal of Cancer, 2018, 142, 2375-2382.	5.1	26
9	Wilms tumour 1 peptide vaccine as a cureâ€oriented postâ€chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse. British Journal of Haematology, 2018, 182, 287-290.	2.5	20
10	Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine. Future Science OA, 2016, 2, FSO96.	1.9	15
11	Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides. Oncotarget, 2018, 9, 36029-36038.	1.8	15
12	Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity. Oncotarget, 2018, 9, 34132-34141.	1.8	14
13	An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells. PLoS ONE, 2015, 10, e0144594.	2.5	13
14	A case of immune recovery vitritis induced by donor leukocyte infusion for the treatment of cytomegalovirus retinitis. European Journal of Haematology, 2005, 75, 352-354.	2.2	10
15	Early detection of cytomegalovirus-specific cytotoxic T lymphocytes against cytomegalovirus antigenemia in human leukocyte antigen haploidentical hematopoietic stem cell transplantation. Annals of Hematology, 2015, 94, 1707-1715.	1.8	10
16	What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia. Expert Review of Hematology, 2019, 12, 211-213.	2.2	10
17	Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms. PLoS ONE, 2015, 10, e0130578.	2.5	10
18	Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain. Science Translational Medicine, 2022, 14, eaax7706.	12.4	10

#	Article	IF	Citations
19	Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects. Expert Review of Hematology, 2014, 7, 671-681.	2.2	8
20	Cellular and Humoral Immune Responses Induced by an HLA Class Iâ€“restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer. Journal of Immunotherapy, 2022, 45, 56-66.	2.4	8
21	Different mechanisms causing loss of mismatched human leukocyte antigens in relapsing t(6;11)(q27;q23) acute myeloid leukemia after haploidentical transplantation. European Journal of Haematology, 2012, 89, 497-500.	2.2	7
22	Two distinct effector memory cell populations of WT1 (Wilmsâ€™ tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients. Cancer Immunology, Immunotherapy, 2015, 64, 791-804.	4.2	7
23	Low incidence of HHVâ€6 reactivation in haploidentical hematopoietic stem cell transplantation with corticosteroid as graftâ€vsâ€host disease prophylaxis compared with cord blood transplantation. Transplant Infectious Disease, 2019, 21, e13073.	1.7	7
24	Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells. Anticancer Research, 2015, 35, 1251-61.	1.1	7
25	Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients. Stem Cell Investigation, 2016, 3, 90-90.	3.0	6
26	Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis. PLoS ONE, 2016, 11, e0152326.	2.5	6
27	Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides. Cancer Immunology, Immunotherapy, 2021, 70, 253-263.	4.2	6
28	Biased usage of T cell receptor Î²â€chain variable region genes of Wilmsâ€™ tumor gene (WT1)â€specific CD8⁺ T cells in patients with solid tumors and healthy donors. Cancer Science, 2012, 103, 408-414.	3.9	5
29	Readerâ€free ELISPOT assay for immunoâ€monitoring in peptideâ€based cancer vaccine immunotherapy. Biomedical Reports, 2020, 12, 244-250.	2.0	5
30	Direct antiglobulin test-negative autoimmune hemolytic anemia associated with HLA-haploidentical stem cell transplantation. International Journal of Hematology, 2011, 93, 558-560.	1.6	3
31	Imaging Assessment of Tumor Response in the Era of Immunotherapy. Diagnostics, 2021, 11, 1041.	2.6	3
32	Identification of mouse helper epitopes for WT1-specific CD4+ T cells. Cancer Immunology, Immunotherapy, 2021, 70, 3323-3335.	4.2	3
33	WT1 epitopeâ€specific IgG and IgM antibodies for immuneâ€monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine. Oncology Letters, 2022, 23, 65.	1.8	3
34	An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells. Journal of Immunotherapy, 2016, 39, 127-139.	2.4	2
35	Enhanced immune reaction resulting from co-vaccination of WT1 helper peptide assessed on PET-CT. Medicine (United States), 2020, 99, e22417.	1.0	2
36	Distinct difference in tumor-infiltrating immune cells between Wilmsâ€™ tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies. Neuro-Oncology Advances, 2021, 3, vdab091.	0.7	2

#	Article	IF	Citations
37	Fatal progression of bronchiolitis obliterans in spite of complete remission of follicular lymphoma and paraneoplastic pemphigus. Annals of Hematology, 2021, , 1.	1.8	2
38	T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy. Frontiers in Immunology, 0, 13, .	4.8	2
39	WT1 Peptide Vaccine for the Treatment of Malignancies: Its Development, Recent Progress, and Future Perspectives. , 2016, , 159-185.		1
40	Dasatinib-induced rapid regression and complete molecular remission of multiple subcutaneous tumours presenting as relapsed chronic myeloid leukaemia after cord blood transplantation. Leukemia Research, 2011, 35, 1658-1659.	0.8	0